SCHEMBL23364110

SCHEMBL23364110

Cc1ccc(S(=O)(=O)OCCC2CC3(CCN(C(=O)O)CC3)C(=O)N2)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
HTR7 P34969 3/20 0.34
STAT3 P40763 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
OTUD7B Q6GQQ9 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
CYP2D6 P10635 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552586 1.00 ALDH1A1 (0.34) ALDH1A1HTR7STAT3POLBMAPT
SCHEMBL21552625 1.00 ALDH1A1 (0.34) ALDH1A1HTR7STAT3POLBMAPT
SCHEMBL28537559 0.88 GPR119 (0.46) KMT2A
SCHEMBL28537557 0.88 GPR119 (0.46) KMT2A
SCHEMBL28537628 0.88 GPR119 (0.46) KMT2A
SCHEMBL21552576 0.85 CA12 (0.38) ALDH1A1STAT3NPSR1CYP2D6KMT2A
SCHEMBL21552575 0.85 CA12 (0.38) ALDH1A1STAT3NPSR1CYP2D6KMT2A
SCHEMBL21552587 0.81 GPR119 (0.36) ALDH1A1STAT3HPGDNPSR1ITGB3
SCHEMBL21552627 0.81 GPR119 (0.36) ALDH1A1STAT3HPGDNPSR1ITGB3
SCHEMBL21552671 0.81 CA12 (0.35) ALDH1A1STAT3MAPTHPGDCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE PRAEVENTIX, LLC 2023-01-05 US disclosed
EP-4058455-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE Temple University - Of The Commonwealth System of Higher Education (US) 2022-09-21 EP disclosed
WO-2021097116-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002383-A1 NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE HTR7, HTR1A, HTR2C ALDH1A1 3128/4885HTR7 1/4885STAT3 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.